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Abstract – A few studies have been devoted to the metabolic syndrome and insulin resistance study in artharagra, 
which showed the syndrome presence and its characteristic insulin resistance in the overwhelming patients’ number. Only a 
few studies have reported on the insulin resistance effect and hyperinsulinemia on the artharagra course, in particular on 
the articular syndrome and other clinical disease manifestations. Nevertheless, they showed a high incidence of metabolic 
syndrome and its characteristic insulin resistance in the vast majority patients with artharagra. 
A direct relationship was revealed between the individual metabolic syndrome components, in particular, insulin 
resistance and hyperinsulinemia, and the hyperuricemia severity, which is accompanied by a more severe artharagray 
arthritis course in patients with artharagra. 
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1. Introduction 
Purpose of the work: To study the severity features of clinical manifestations, data from instrumental and laboratory 
studies in patients with artharagra occurring in combination with metabolic syndrome. 
Study object. Two samples were examined:  
1. A representative the unorganized population sample at age 40 to 69 in 1335 people. 
2. Patients sample with artharagra that underwent treatment at the Republican rheumatological center department of 
Tashkent medical academy in 120 people at age 40 - 69.  
Study subject. The clinical course features of artharagra in MS were studied; 
2. Research results. 
 To assess the severity characteristics of the artharagra clinical course, the artharagra severity index (ASI) was used, 
developed at Rheumatology institute of Russian medical sciences academy (Table 1). This index includes a number of 
parameters characterizing the clinical artharagra severity; the artharagra severity index was calculated taking into account the 
presence and the articular syndrome severity, the uric acid level and the reIG tenological picture. 
The artharagra severity index calculation was carried out on the basis of I.A. Yakunina (2006) recommendations according 
to the following formula: 
Tophus (0-no, 1-present)  
+ number of tofus/40  
+ number of affected joints at examination/28  
+ number of affected joints during the entire period of illness/28  
+ number of exacerbations in the last year/12  
+ duration of the last exacerbation (in weeks)/52  
+ patient's age (number of full years)/65  
+ uric acid level (μmol / l)/420 = IT. 
Table1. 
Artharagra severity index for different age groups in impaired glucose tolerance (IGT) 
Observations number (n) 
Age Normoglycemia IGT The overall result 
40-49 years old 18 22 40 
50-69 years old 15 65 80 
The overall result 33 87 120 
 
Average values (М+m) 
Age Normoglycemia IGT The overall result 
40-49 years old 2,75±0,07 3,49±0,06 # 3,16±0,5 
50-69 years old 3,74±0,08 * 3,68±0,05 3,69±0,04 * 
The overall result 3,21±0,05 3,61±0,04 3,49±0,03 
Note: *) - the table shows the reliability of the differences in age groups, 
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    #) – differences between groups with normoglycemia and hyperglycemia. 
According to the data obtained, the artharagra severity index at age 50-69 is significantly more common than at age 40-49. 
At the same time, the artharagra severity levels index among persons with hyperglycemia in the younger age group (40-49 
years old) were significantly higher than among persons with normal glycemic levels.  
 From the data obtained, it can be concluded that hyperglycemia significantly aggravates the artharagra clinical course. 
However, hyperglycemia plays this role to a greater extent before at age 50. At the same time, a significantly artharagra 
severity higher level index with normal glycemia among people at age 50-69 years indicates that age is a risk factor for a 
more severe artharagra course, impaired glucose tolerance independent. 
Considering that one of the objectives of this study was to study various hyperglycemia categories role, and then the 
artharagra severity indices index among people with impaired fasting glycemia and post-load hyperglycemia were studied 
(Table 2). 
Table 2. 
Artharagra severity index in different age groups with different glycemia categories  








40-49 years old 18 8 14 40 
50-69 years old 15 3 62 80 
The overall result 33 11 76 120 








40-49 years old 2,75±0,08 3,83±0,11 # 3,26±0,09 # 3,16±0,07 
50-69 years old 3,74±0,09 * 3,66±0,14 3,68±0,08 3,69±0,06 * 
The overall result 3,21±0,07 3,78±0,10 3,57±0,07 3,49±0,08 
Note: *) - the table shows the reliability of differences in age groups, 
                           #) – differences between groups with normoglycemia and hyperglycemia ± 
 The findings indicate that both fasting and post-load hyperglycemia contribute to the worsening of the artharagra 
clinical course. At the same time, fasting hyperglycemia contributes more to the increase in the artharagra severity index 
than post-load hyperglycemia.  
It should be noted that both hyperglycemia types, as well as impaired glucose tolerance in general, have their predominant 
negative effect on the clinical course of artharagra among people at age 40-49. 
Note that impaired glucose tolerance is only one of the metabolic syndrome components. At the same time, the objectives of 
our study were to study metabolic syndrome role in general on the artharagra clinical course. 
In this regard, the average indicators of the artharagra severity index in persons with metabolic syndrome, were considered 
occurring against the impaired glucose background tolerance. 
Table 3. 
Artharagra severity index among persons with metabolic syndrome and impaired glucose tolerance 
Observations number (n) 
Presence of metabolic syndrome Norm 
Impaired glucose 
tolerance 
The overall result 
Have metabolic syndrome 13 87 100 
No metabolic syndrome 20 - 20 
Total 33 87 120 
Average values (М+m) 
Presence of metabolic syndrome Norm 
Impaired glucose 
tolerance 
The overall result 
Have metabolic syndrome 3,38±0,10 3,61±0,07 3,58±0,8 * 
No metabolic syndrome 3,08±0,09 - 3,08±0,09 
Total 3,20±0,08 3,61±0,06 3,49±0,07 
Note: *) - the reliability of the differences between the groups with and without MS is indicated, 
  
As follows from the data shown in Table 3, the artharagra severity index level among people with metabolic syndrome is 
significantly higher than among people who do not have this syndrome. This confirms the important role of metabolic 
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syndrome in the pathogenesis of artharagra.  
However, according to the modern classification of metabolic syndrome, it can be recorded not only when all 4 of its 
components are present, but also in the 3 presence components. This interpretation of metabolic syndrome diagnosis is due 
to the fact that, along with impaired glucose tolerance, other components can also contribute to the formation of a more 
severe course of artharagra. 
Therefore, further we analyzed the average indicators of the artharagra severity index among individuals with different 
numbers of individual components of the metabolic syndrome (Table 4.).  
Table 4. 
Artharagra severity Index among individuals with different amounts 
Individual components of the metabolic syndrome with impaired glucose tolerance  
Observations number (n) 
Number of components Normal glucose tolerance 
Impaired glucose 
tolerance 
The overall result 
1 5 - 5 
2 14 1 15 
3 14 22 36 
4 (complete metabolic 
syndrome) 
- 64 64 
Total 33 87 120 
Average values (М+m) 
Number of components Normal glucose tolerance 
Impaired glucose 
tolerance 
The overall result 
1 2,41±0,18 - 2,41±0,18 
2 3,26±0,09 3,55±0,0 3,28±0,09 
3 3,39±0,10 * 3,62±0,08 3,54±0,09 * 
4 (complete metabolic 
syndrome) 
- 3,60±0,06 3,59±0,06 * 
Total 3,20±0,07 3,61±0,05 3,49±0,06 
Note: *) - the differences reliability for the group with 1 MS component is indicated  
 
3. Conclusions: 
According to the obtained data, in general, as the number of metabolic syndrome components increases, the artharagra 
severity index increases. Moreover, the differences in the value of the index of severity of artharagra among persons with 
one component of the metabolic syndrome are significantly lower than those with 3 or 4 components of the metabolic 
syndrome. 
 In the group of persons with normal glucose tolerance, an increase in the ASI level is also observed. At the same 
time, the differences in the artharagra severity index level between the groups with the 1st and 3rd components of the 
metabolic syndrome were statistically significant. 
Thus, we can conclude that, in general, an increase in the number of metabolic syndrome components contributes to clinical 
course aggravation of artharagra, as evidenced by an increase in the artharagra severity index. 
The artharagra severity index (ASI), which reflects the clinical course severity of this disease and the uric acid level, has a 
direct correlation with the glycemic and inverse relationship with the postglycemic coefficient, which indicates the 
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